

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/010192-2021>

Contract

Supply of Whole Blood Collection System and Ancillary Processing Systems

NHS Blood & Transplant

F20: Modification notice

Notice identifier: 2021/S 000-010192

Procurement identifier (OCID): ocids-h6vhtk-02af41

Published 10 May 2021, 10:55pm

Section I: Contracting authority/entity

I.1) Name and addresses

NHS Blood & Transplant

North Bristol Park

Filton, Bristol

Email

Gabriella.Lesca@nhsbt.nhs.uk

Telephone

+44 7385387928

Country

United Kingdom

NUTS code

UK - United Kingdom

Internet address(es)

Main address

<https://www.nhsbt.nhs.uk>

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Supply of Whole Blood Collection System and Ancillary Processing Systems

Reference number

NHSBT0763

II.1.2) Main CPV code

- 33141613 - Blood bags

II.1.3) Type of contract

Supplies

II.2) Description

II.2.1) Title

Whole Blood Collection Systems (Lot 1) and Ancillary Processing Systems (Lot2)

II.2.2) Additional CPV code(s)

- 33141630 - Blood plasma filters

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

United Kingdom, Ireland, Australia, and New Zealand

II.2.4) Description of the procurement at the time of conclusion of the contract:

On the 9th June 2017, this tender (EuroBloodPack 2) for the Supply Whole Blood and Ancillary Processing Systems was awarded under a Framework Agreement with the notice number <https://ted.europa.eu/udl?uri=TED:NOTICE:155066-2016:TEXT:EN:HTML> with subsequent contract award notice 2017/S 128-260952

<https://ted.europa.eu/udl?uri=TED:NOTICE:260952-2017:TEXT:EN:HTML>

EuroBloodPack 2 was run by NHSBT, working with other European Blood Alliance members (full details of the EBA and their members are available at www.europeanbloodalliance.eu/ updated from time to time), the Australian Blood Service (ARCBS) and New Zealand Blood Service (NZBS) who were all potential beneficiaries to the agreement. To note, those beneficiaries are eligible to place orders but not mandated.

EuroBloodPack 2 is divided in two Lots respectively: Whole Blood Collection System (Lot 1) and Ancillary Processing System (Lot 2).

Lot No 1: To supply Bottom and Top, Top and Top and Dry Packs.

Lot No 2: To supply: Quadruple transfer system for the storage of platelets for neonatal use, Quadruple transfer system for the storage of frozen plasma for neonatal use, Quadruple transfer system for the storage of red cells for neonatal use, Sextuplet transfer system for the storage of red cells for neonatal use, Single transfer pack for the handling of waste material or storage of plasma components, Cryoprecipitate pooling system, Plasma filter system — single storage pack, In-process filter system for platelets, Platelet storage system, Platelet pooling filter system, Platelet pooling filter system incorporating integral sampling device.

II.2.7) Duration of the contract, framework agreement, dynamic purchasing system or concession

Start date

9 June 2017

End date

31 March 2023

In the case of framework agreements, provide justification for any duration exceeding 4 years

Need for modification brought about by circumstances which a diligent contracting authority could not foresee. See sections VII2.1 and VII2.2

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.2) Administrative information

IV.2.1) Contract award notice concerning this contract

Notice number: [2017/S 128-260952](#)

Section V. Award of contract/concession

Contract No

NHSBT0763

V.2) Award of contract/concession

V.2.1) Date of conclusion of the contract/concession award decision:

9 June 2017

V.2.2) Information about tenders

The contract/concession has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor/concessionaire

MacoPharma GMP.b, Haemonetics S.A, Fresenius Kabi Limited

Mouscron, Runcorn, Signy

Country

United Kingdom

NUTS code

- UK - United Kingdom

The contractor/concessionaire is an SME

No

V.2.4) Information on value of the contract/lot/concession (at the time of conclusion of the contract;excluding VAT)

Total value of the procurement: £70,000,000

Section VI. Complementary information

VI.4) Procedures for review

VI.4.1) Review body

High Courts of Justice

London

Country

United Kingdom

Section VII: Modifications to the contract/concession

VII.1) Description of the procurement after the modifications

VII.1.1) Main CPV code

- 33141613 - Blood bags

VII.1.2) Additional CPV code(s)

- 33141630 - Blood plasma filters

VII.1.3) Place of performance

NUTS code

- UK - United Kingdom

Main site or place of performance

United Kingdom, Ireland, Australia, and New Zealand

VII.1.4) Description of the procurement:

The EuroBloodPack 2(EBP2) framework agreement has a duration of four years and is due to expire on the 9th June 2021. This Modification will extend the EBP2 Framework Agreement to 31st March 2023.

VII.1.5) Duration of the contract, framework agreement, dynamic purchasing system or concession

Start date

9 June 2017

End date

31 March 2023

In the case of framework agreements, provide justification for any duration exceeding 4 years:

See sections VII2.1 and VII2.2

VII.1.6) Information on value of the contract/lot/concession (excluding VAT)

Total value of the contract/lot/concession:

£70,000,000

VII.1.7) Name and address of the contractor/concessionaire

MacoPharma GMP.b, Haemonetics S.A, Fresenius Kabi Limited

Mouscron, Runcorn, Signy

Country

United Kingdom

NUTS code

- UK - United Kingdom

The contractor/concessionaire is an SME

No

VII.2) Information about modifications

VII.2.1) Description of the modifications

Nature and extent of the modifications (with indication of possible earlier changes to the contract):

The EuroBloodPack 2(EBP2) framework agreement has a duration of four years and is due to expire on the 9th June 2021. This Modification will extend the EBP2 Framework until 31st March 2023. Due to the impact of Covid-19 and the support for the Convalescent Plasma (CVP) programme there has been a significant delay in the

retendering the new supply and in developing the replacement International Blood Pack 1 (IBP1) Framework on time.

VII.2.2) Reasons for modification

Need for modification brought about by circumstances which a diligent contracting authority/entity could not foresee.

Description of the circumstances which rendered the modification necessary and explanation of the unforeseen nature of these circumstances:

This Modification Notice is to provide notice that the EBP2 is being modified in accordance with Regulation 72 .1. B and /or 72.1.C of the Public Contracts Regulations 2015. This is because of the continuing focus of the contracting authorities on the Covid-19 crisis (which no diligent contracting authority could have foreseen) has significantly reduced the technical support for a retender. The length of this time has been chosen so that the replacement Framework IBP1 can be completed. The length of time of this extension is because any other interim arrangements would be in place for such a short duration that it would cause significant inconvenience and/ or substantial duplication of costs; along with causing significant technical barriers such as requirements of interchangeability or interoperability with existing equipment, services or installations procured under the initial procurement.

VII.2.3) Increase in price

Updated total contract value before the modifications (taking into account possible earlier contract modifications, price adaptations and average inflation)

Value excluding VAT: £70,000,000

Total contract value after the modifications

Value excluding VAT: £104,000,000